Welcome!

SYS-CON UK Authors: Salvatore Genovese, Jamie Matusow

News Feed Item

Free Research Reports on IMUC, NBIX, OPXA and PLX Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY -- (Marketwire) -- 02/06/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) posted a gain of 10 percent on more than three-times the average daily volume Tuesday. The company has recently reported that the FDA has approved their investigational new drug application for ICT-140, a treatment for ovarian cancer.

Find out more about ImmunoCellular including full access to the free equity report at: www.BedfordReport.com/IMUC

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares gained 12 percent on nearly five-times the average daily volume Tuesday. The company recently reported that it has been granted two additional patents related to its proprietary VMAT2 inhibitor. The company is scheduled to release its result for the fourth quarter on Friday, February 8th.

Find out more about Neurocrine Biosciences including full access to the free equity report at: www.BedfordReport.com/NBIX

Opexa Therapeutics Inc. (NASDAQ: OPXA) shares soared 165 percent on over 8 million shares traded Tuesday. The company and Merck Serono have enetered into an option and license agreement for the development and commercialization of Tcelna for the treatment of multiple sclerosis.

Find out more about Opexa Therapeutics including full access to the free equity report at: www.BedfordReport.com/OPXA

Protalix BioTherapeutics Inc. (NYSE: PLX) shares surged 17 percent on a large volume spike of nearly 7 million shares traded Tuesday. The company reported that it has engaged Citigroup to assist in reviewing "a broad array of product partnering, technology sharing and other strategic alternatives."

Find out more about Protalix BioTherapeutics including full access to the free equity report at: www.BedfordReport.com/PLX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:
Equity News Circuit
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.